checkAd

     117  0 Kommentare Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications - Seite 2

    Communications

    The Company expects to file Form 10-Q for Q1 2023 on or before Friday, May 12th, 2023, along with issuing a corresponding press release containing first quarter highlights after market close at approximately 5:00pm (EDT) on the same day.

    Shareholders can also expect consistent updates issued as press releases as progress is made in each of the areas outlined in the Fix, Fund, Propel framework.

    About Navidea

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, visit www.navidea.com.

    About G2G Ventures

    G2G Ventures is a Colorado-based private equity firm focused on empowering organizations to reach their full potential through investment and consulting services. Specializing in creating long-term partnerships with trusted investors and established businesses, G2G Ventures draws on strong internal balance sheet liquidity, augmented by trusted investor capital, to craft bespoke capital solutions which include private equity investment, venture capital participation, and mezzanine debt options. Beyond financial investment, G2G Ventures provides accretive consulting services to help clarify strategic goals and key performance indicators (KPIs), evolve financial processes, and enhance operational effectiveness. To learn more about how G2G Ventures is a growth partner for enduring business, connect with our team.

    Seite 2 von 3



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications - Seite 2 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the introduction of a Fix, Fund, Propel approach …

    Schreibe Deinen Kommentar

    Disclaimer